An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

NCT02225574 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class

Stopped Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II

Conditions

Interventions

Sponsor

M.D. Anderson Cancer Center

Collaborators